Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)

Market Cap	10.04B +36.9%
Revenue (ttm)	247.05M -1.4%
Net Income	22.96M -65.0%
EPS	0.10 -76.1%
Shares Out	205.43M
PE Ratio	437.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,621,359
Average Volume	5,911,931
Open	50.05
Previous Close	48.88
Day's Range	49.80 - 51.86
52-Week Range	33.34 - 83.60
Beta	-0.44
RSI	39.56
Earnings Date	Apr 28, 2026

About SHA:688091

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 415
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688091

Financial Performance

In 2024, SHA:688091's revenue was 173.53 million, a decrease of -51.83% compared to the previous year's 360.25 million. Earnings were 6.98 million, a decrease of -95.68%.